
Eli Lilly and Company, Viking Therapeutics, and Johnson & Johnson are the three Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool. Pharmaceutical stocks are shares of publicly traded companies involved in discovering, developing, manufacturing, or selling medicines and other healthcare products. For stock market investors, these stocks represent ownership in the companies and may offer growth potential, though their performance can be significantly affected by clinical-trial results, regulatory approvals, patent expirations, competition, and healthcare policies. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Viking Therapeutics (VKTX)
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Read Our Latest Research Report on VKTX
Johnson & Johnson (JNJ)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Read Our Latest Research Report on JNJ
Featured Stories
- MarketBeat’s Top Five Stocks to Own in September 2026
- SanDisk’s $1,800 Breakout Turns Memory Hardware Into a Profit Story
- Is Palantir Worth $250 or $1? Bulls and Burry Arrive at Opposite Conclusions
- 3 Restaurant Stocks Near 52-Week Lows as Consumer Pressure Builds
- Meta One Subscriptions Show Positive Early Signs, Analysts Forecast Long-Term Growth
- Is the Market Right or Wrong About These 4 High Short Interest Stocks?
